This record provides bibliographic details and links to the original research. An editorial study breakdown is not available.
Mirończuk-Chodakowska and Witkowska (2020) · International Journal of Environmental Research and Public Health
- Population
- 68 freeze-dried fruiting-body samples from 18 wild edible Polish species and 3 commercial cultivated species, with three to four samples per species
- Intervention
- Dual beta-glucan measurement using the Megazyme enzymatic assay plus the Congo red assay intended to highlight triple-helix-positive glucans
- Comparator
- Wild versus commercial mushrooms, plus species-by-species shifts when the assay method changed
- Finding
- Wild mushrooms looked broadly comparable to familiar commercial species on total beta-glucans, but the Congo red ranking pushed Lactarius deliciosus and Suillus grevillei to the top.
preliminary This is a useful full-text-reviewed composition paper, but it is still a measurement paper, not evidence that eating these mushrooms improves human health.
Mirończuk-Chodakowska and Witkowska (2020), Abstract and Tables 1-3
Key Numbers
The numbers most worth remembering
68
Samples analyzed
3 to 4 samples per species
21
Edible species
18 wild and 3 commercial
34.97
Top wild Megazyme value
Tricholoma portentosum, g/100 g DM
17.11
Top Congo red value
Lactarius deliciosus, g/100 g DM
The key lesson is not just which species ranked first. It is that the rankings moved once the authors switched from a total-glucan assay to a Congo red assay aimed at triple-helix-positive glucans.
Mirończuk-Chodakowska and Witkowska (2020), Tables 1-3 and Figure 2
- Collection
Wild and commercial mushrooms were gathered into one screen
- The authors studied 18 wild edible species collected from seven municipalities in northeastern Poland.
- Three commercial cultivated species were bought in local markets for comparison: Agaricus bisporus, Lentinula edodes, and Pleurotus ostreatus.
- Preparation
Only edible fruiting-body material was processed
- About 100 g of edible stem and pileus tissue per sample was frozen, freeze-dried for about 36 hours, and ground before analysis.
- This is a dry-mass composition workflow, not a consumer-use experiment and not an extract-bioavailability study.
- Assay 1
Megazyme estimated total beta-glucans
- The K-YBGL assay kit measured total glucans and alpha-glucans so beta-glucans could be calculated by difference.
- This method is better read as a total beta-glucan screen than as a structural assay.
- Assay 2 and stats
Congo red targeted a narrower structural signal
- A three-stage acid/alkali extraction fed a Congo red spectrophotometric assay intended to capture triple-helix-positive beta-glucans.
- The authors then used non-parametric statistics to compare wild and commercial groups and to compare extraction fractions.
Mirończuk-Chodakowska and Witkowska (2020), Methods
What This Paper Actually Asked
This was not a trial of immune outcomes, cancer outcomes, or even extract performance.
It was a lab composition paper asking a narrower question: which edible mushrooms look richer in beta-glucans once you actually measure dried fruiting bodies, and how much does the answer change when the assay method changes?
That second question is the one that makes the paper more useful than a generic "mushrooms contain beta-glucans" citation.
What The Full Paper Adds
The abstract gives the headline values, but the full paper makes the limitations and context much clearer.
- The authors did not just compare wild mushrooms with each other. They also compared them with three familiar cultivated reference mushrooms.
- Pleurotus ostreatus still posted the single highest Megazyme value overall at 40.34 g/100 g dry mass, which keeps the paper from becoming a simplistic "wild always beats cultivated" story.
- The wild-versus-commercial comparison in Table 3 did not reach statistical significance on the Megazyme comparison or on the summed Congo red fractions.
- The paper also showed that the gap between methods could be large. Cantharellus cibarius had a greater than 90% difference between the Congo red and Megazyme readings.
That last point matters most. If a species moves sharply when the method changes, then the number is telling you something about assay behavior and glucan conformation, not just "how medicinal" the mushroom is.
Why The Two Methods Matter
The Megazyme assay and the Congo red assay are not interchangeable.
Megazyme is best understood here as a broader total beta-glucan estimate. Congo red is narrower and is supposed to be more sensitive to triple-helix-positive glucans after a staged extraction workflow.
That is why the species ranking shifts:
- Tricholoma portentosum led the wild mushrooms on Megazyme at 34.97 g/100 g dry mass.
- Lactarius deliciosus and Suillus grevillei led the Congo red screen at 17.11 and 16.97 g/100 g dry mass.
- Wild mushrooms looked numerically competitive with the commercial references, but the group-level comparisons still failed to clear conventional significance thresholds.
If you only cite one number from one assay, you are missing the main finding of the paper.
Methods Audit
Methods Audit
Where this design is useful and where it still leaks uncertainty
Species coverage: strong for a composition screen
Sixty-eight samples across 21 edible species is a real data set, not a token single-species assay.
Sample geography: still narrow
The wild material came from one Polish region, so these numbers should not be treated as universal species constants.
Method triangulation: useful but incomplete
Running both Megazyme and Congo red was more informative than using either alone, but the paper did not add direct structural confirmation such as NMR.
Outcome relevance: indirect
This paper measures glucan content in dried fruiting bodies. It does not test extraction yield in finished products, oral absorption, or any human endpoint.
Mirończuk-Chodakowska and Witkowska (2020), Methods, Figure 2, and Table 3
What You Can And Cannot Take From It
The most defensible reading is not that wild mushrooms are clinically better than cultivated medicinal mushrooms.
The most defensible reading is smaller:
- several wild edible species looked compositionally competitive as beta-glucan sources
- the answer depended meaningfully on whether the authors used a broad enzymatic assay or a conformation-sensitive Congo red workflow
- the paper supports beta-glucan sourcing and screening questions much more than it supports consumer-health claims
That is still useful. It is just a different kind of usefulness from what supplement marketing usually wants.
Most Defensible Claims
Most Defensible Claims
Claims a careful reader could actually cite from this page
Some wild edible mushrooms look compositionally competitive with familiar cultivated species
That is the paper's clearest contribution, especially for Lactarius deliciosus, Suillus grevillei, and Tricholoma portentosum.
Assay choice changes both rankings and interpretation
The same species can look very different once the paper moves from Megazyme to Congo red, which is exactly why single-number summaries are fragile.
The paper does not prove that wild mushrooms outperform cultivated medicinal species overall
The group-level wild-versus-commercial comparisons in Table 3 did not show statistically significant differences.
The paper does not prove a human health benefit from eating these mushrooms
No human dosing, no bioavailability testing, and no clinical outcomes were measured here.
Mirończuk-Chodakowska and Witkowska (2020), Tables 1-3 and Conclusions
Reasons This Study Might Be Wrong
Skeptical Read
The main reasons not to over-update on this paper
Species values are not fixed constants
The paper itself notes that species, environment, substrate, maturity, and even strain can shift beta-glucan content.
Three to four samples per species is not a huge within-species base
That is reasonable for a screen, but it still leaves plenty of room for local harvest conditions to move the averages.
Congo red is an indirect structural proxy
The paper treats it as a way to detect triple-helix-positive beta-glucans, but it is still not the same thing as a full structural characterization workflow.
Dry-mass glucan content is not the same thing as consumer benefit
A mushroom can look rich on paper and still behave very differently once extraction, cooking, digestion, and dosing enter the picture.
Mirończuk-Chodakowska and Witkowska (2020), Discussion and Conclusions
What Happened Next
- 2017
A larger enzymatic screening paper had already shown wild species can score high
- Sari et al. screened cultivated and wild mushrooms for beta-glucans and reported that many wild-growing species had notable values, especially among bracket fungi.
- That earlier work set up the basic sourcing question but did not make the same dual-assay point this 2020 paper makes.
- 2020
This paper sharpened the question by adding a second assay
- The real advance here was not just another species list. It was showing how a conformation-sensitive assay can reshuffle the ranking produced by a broader enzymatic method.
- That makes the paper more useful for measurement skepticism than for headline hunting.
- 2023
Extraction work reinforced that beta-glucan yield depends on species and fraction
- Pérez-Bassart et al. showed that different mushroom species distribute beta-glucans differently across aqueous, alkaline, and residual fractions.
- That supports the broader message that there is no single context-free glucan number for a mushroom.
- 2023
A dedicated mushroom-glucans review kept the structure question front and center
- Vetter's 2023 review emphasized that branching, solubility, and conformation are central to how mushroom glucans should be interpreted biologically.
- That fits this page's main caution: composition data are useful, but only if you keep structure and method in view.
Sari et al. (2017), PMID 27596390; Mirończuk-Chodakowska and Witkowska (2020); Pérez-Bassart et al. (2023), PMID 36126575; Vetter (2023), PMID 36900525
Related follow-up sources: Sari et al. 2017, Perez-Bassart et al. 2023, and Vetter 2023.
Funding And Conflicts
The paper states that the research received no external funding, and the authors declared no conflict of interest.
That is a cleaner funding profile than many mushroom-health papers. The bigger caution here is not sponsor bias. It is the temptation to treat a compositional screen like a health-outcomes study.
Rethink Takeaway
This is a useful full-text-reviewed map of where beta-glucans show up in a set of wild Polish edible mushrooms. It does support the idea that some wild species are credible glucan sources, and it does show that assay choice can materially change the ranking.
What it does not support is the leap from "higher measured beta-glucan content" to "better real-world medicinal effect." If someone cites this paper as proof that wild mushrooms deliver superior immune or anticancer outcomes, they are skipping the hard part of the evidence chain.
Read the original research
Evaluation of Polish wild Mushrooms as Beta-Glucan Sources.
International journal of environmental research and public health, 17(19)
Citation
Mirończuk-Chodakowska, Iwona; Witkowska, Anna Maria. (2020). Evaluation of Polish wild Mushrooms as Beta-Glucan Sources.. International journal of environmental research and public health, 17(19). https://doi.org/10.3390/ijerph17197299